Wise Choices in the Intensive Care Unit
Launched by KAROLINSKA INSTITUTET · Jun 2, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The WICH-ICU trial is a research study designed to explore whether a program called the Choosing Wisely campaign can be safely introduced in intensive care units (ICUs) without putting critically ill patients at risk. This campaign encourages doctors to question the necessity of certain tests and treatments that may not benefit patients and could even be harmful. In Sweden, where the study is taking place, many patients in ICUs undergo frequent tests, and this trial aims to see if reducing unnecessary procedures can improve patient care and save healthcare costs.
To participate in this trial, patients need to be at least 18 years old and receiving treatment in a Swedish ICU. The study will track important outcomes, such as the rate of survival 30 days after treatment and how long patients stay in the ICU. Participants can expect their health data to be collected from a national registry to help researchers understand the effects of the Choosing Wisely campaign. Overall, this trial is an important step in ensuring that ICU patients receive the best possible care while also considering the costs involved in their treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients 18 years or older, treated in Swedish ICU's
- Exclusion Criteria:
- • Patients under the age of 18 years
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Stockholm, , Sweden
Patients applied
Trial Officials
Max B Bell, MD, PhD
Principal Investigator
N32276 PMI/Karolinska
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported